-
232 Reads
|
0 Comments
|
June 17, 2015
Latest Update from Hybridan The Biopharmaceutical Corporation has today updated on progress by its strategic partner in Russia GENERIUM Pharmaceuticals, a vertically integrated biotech company. The construction of Generium’s GMP plasma Purification facility is progressing rapidly and ahead of the originally anticipated timelines. The facility designed to process up ...
-
818 Reads
|
1 Comment
|
May 14, 2015
Canaccord Genuity comments on ProMetic Life Sciences Inc. According to Canaccord Genuity: http://personal.crocodoc.com/kV4j1Sc ProMetic Life Sciences Inc. RATING: BUY (unchanged) PRICE TARGET: C$3.25 (unchanged) Weakness on the back of Q1 results presents a buying opportunity Investment Recommendation ProMetic...
-
402 Reads
|
0 Comments
|
May 11, 2015
.As of 11:59pm ET May 10th, 2015 Filing Date Transaction Date Insider Name Ownership Type Securities Nature of transaction Volume or Value Price May 8/15 May 8/15 Bishop, Andrew Trevor Direct Ownership Options 00 - Opening Balance-Initial SEDI Report May 8/15 May 8/15 Bishop, Andrew Trevor Direct Ownership Common Shares 00 - Opening Balance-Initial SEDI Report 5,000 ...
-
242 Reads
|
0 Comments
|
April 16, 2015
Here is Fred's answerers to a couple of questions I had about the recent financing announcement. Hi Doug, To the contrary, things are going on very well at PLI. The financing was rendered necessary for a few reasons: 1- We needed to have a balance sheet and a cash position that is more in line with our market cap, compared to our peers and with industry standards...
-
406 Reads
|
0 Comments
|
January 20, 2015
Filing Date Transaction Date Insider Name Ownership Type Securities Nature of transaction # or value acquired or disposed of Price Jan 19/15 Jan 16/15 Laurin, Pierre Indirect Ownership Common Shares 10 - Acquisition in the public market 3,900 $1...
-
336 Reads
|
1 Comment
|
September 4, 2014
There's also a summary of an interview with the ceo on the previous post on this blog...must read imo... ProMetic gains on positive pre-IND meeting with FDA for main drug candidateWed 1:47 pm by Deborah Bacal The pre-investigational new drug meeting focused on the company's proposed phase II clinical program for the drug, in patients with...
-
418 Reads
|
0 Comments
|
September 4, 2014
sah1 wrote: Key highlights that stood out for me include: Resin business -14 drugs approved using PLI technology: 28 more in pipeline -resins sales will approach $20-30M next year of which $5M due to recent announcement and $10M due to Octapharma alone (what with the potential of contracts with Halozyme, Novozyme and partners and CNBG $30M more likely in my view than 20M) -excellent growth...
-
359 Reads
|
0 Comments
|
September 3, 2014
ProMetic Reports Successful PBI-4050 Pre-IND Meeting with the FDA LAVAL, QUEBEC--(Marketwired - Sept. 3, 2014) - ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF), ("ProMetic" or the "Corporation") announced today it had a successful Pre-Investigational New Drug ("Pre-IND) meeting with the US Food and Drug Administration ("FDA") for its anti-fibrotic,...